Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor
Hidehiro Ishii(Joslin Diabetes Center), George L. King(Joslin Diabetes Center), Lawrence M. Ballas(SPX Corporation (United States)), Pu Xia(Integrated Chinese Medicine (China)), Sven–Erik Bursell(Joslin Diabetes Center), Daisuke Koya(Kanazawa Medical University), Allen C. Clermont(Joslin Diabetes Center), Lawrence E. Stramm(Eli Lilly (United States)), Chikako Takagi(Joslin Diabetes Center), Michael R. Jirousek(Abbott Fund), Timothy S. Kern(Case Western Reserve University), William F. Heath(Eli Lilly (United States)), Edward P. Feener(KalVista Pharmaceuticals (United States))
Cited by 1,104
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Retinopathy in Diabetes
|Diabetes Care|2004|1.1k
Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications
|Circulation Research|2010|979